Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

895 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Martín M, Zielinski C, Ruiz-Borrego M, Carrasco E, Ciruelos EM, Muñoz M, Bermejo B, Margelí M, Csöszi T, Antón A, Turner N, Casas MI, Morales S, Alba E, Calvo L, de la Haba-Rodríguez J, Ramos M, Murillo L, Santaballa A, Alonso-Romero JL, Sánchez-Rovira P, Corsaro M, Huang X, Thallinger C, Kahan Z, Gil-Gil M. Martín M, et al. Among authors: zielinski c. Eur J Cancer. 2022 Jun;168:12-24. doi: 10.1016/j.ejca.2022.03.006. Epub 2022 Apr 13. Eur J Cancer. 2022. PMID: 35429901 Free article. Clinical Trial.
Impaired production of tumor necrosis factor in breast cancer.
Zielinski CC, Mueller C, Tyl E, Tichatschek E, Kubista E, Spona J. Zielinski CC, et al. Cancer. 1990 Nov 1;66(9):1944-8. doi: 10.1002/1097-0142(19901101)66:9<1944::aid-cncr2820660916>3.0.co;2-w. Cancer. 1990. PMID: 2224791
Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor.
Stöger H, Samonigg H, Krainer M, Ploszczynski M, Nirnberger G, Maca S, Hehenwarter W, Wirth M, Schüller J, Vavra N, Scheithauer W, Kornek G, Stierer M, Zielinski CC. Stöger H, et al. Among authors: zielinski cc. Eur J Cancer. 1998 Mar;34(4):482-8. doi: 10.1016/s0959-8049(97)10039-9. Eur J Cancer. 1998. PMID: 9713297 Clinical Trial.
Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody.
Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, Jasinska J, Kundi M, Wolff K, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H. Hafner C, et al. Among authors: zielinski cc. Int J Cancer. 2005 Apr 10;114(3):426-32. doi: 10.1002/ijc.20769. Int J Cancer. 2005. PMID: 15578703 Free article.
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T. Zielinski C, et al. J Clin Oncol. 2005 Mar 1;23(7):1401-8. doi: 10.1200/JCO.2005.12.106. J Clin Oncol. 2005. PMID: 15735116 Clinical Trial.
Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
Hudelist G, Köstler WJ, Czerwenka K, Kubista E, Attems J, Müller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hoschützky H, Zielinski CC, Singer CF. Hudelist G, et al. Among authors: zielinski cc. Int J Cancer. 2006 Mar 1;118(5):1126-34. doi: 10.1002/ijc.21492. Int J Cancer. 2006. PMID: 16161043 Free article. Clinical Trial.
895 results